The Journal of Clinical & Experimental Oncology (JCEOG) promotes rigorous research that makes a significant contribution in advancing knowledge for cancer diagnosis and therapy. The journal includes all major themes pertaining to medical oncology, surgery, radiotherapy and pediatric oncology.
Clinical & Experimental Oncology is a subscription based journal that provides a range of options to purchase our articles and also permits unlimited Internet Access to complete Journal content. It accepts research, review papers, online letters to the editors & brief comments on previously published articles or other relevant findings in SciTechnol. Articles submitted by authors are evaluated by a group of peer review experts in the field and ensures that the published articles are of high quality, reflect solid scholarship in their fields, and that the information they contain is accurate and reliable.
Proximal-type Epithelioid Sarcoma of the Head and Neck (HN): A Study with Immunohistochemical and Molecular Analysis of SMARCB1
Proximal-type epithelioid sarcoma is an aggressive variant of epithelioid sarcoma most often occurring in soft tissues of the proximal limbs, characterized by polygonal cells, marked nuclear atypia, and varied rhabdoid features. Malignant rhabdoid tumor is an aggressive, well characterized entity typically with rhabdoid morphology and involving the kidney of pediatric patients. Rarely, tumors with morphologic and biologic features identical to those in kidney occur in extra-renal sites and are regarded as an extrarenal presentation of the same entity in kidney, named malignant extra-renal rhabdoid tumor.
Schwannoma of the Palatine Tonsil: A Rare Entity in an Eight Year Old Girl
Objective: We present a case of tonsillar schwannoma occurring in the youngest patient described in the English literature.
Results: An eight year old girl was found to have a 12 month history of slowly progressive dysphagia and two month history of a rapidly enlarging right sided oropharyngeal mass. A right sided tonsillectomy was performed and while there was an involved margin, the MRI post excision showed no residual tumour or abnormal enhancement. The final histology demonstrated the
lesion to be a schwannoma.
Conclusion: This represents an important addition to the literature as there have only been eight other cases of tonsillar schwannoma described in the literature, two of which had been in children. This case represents the youngest patient reported to date.
Central Mucoepidermoid Carcinoma–A Case Report and Review of the Literature
Mucoepidermoid carcinoma is one of the most common malignancies of the salivary glands. Central mucoepidermoid carcinomas are extremely rare in the jaws, representing about 2 to 4% of all mucoepidermoid carcinomas. The case presented is a 43 year old woman with central mucoepidermoid carcinoma on the left side of the mandible. She did not visit surgeon for further treatment and died due to heart disease after 3 months. Although more than 100 cases have been reported in the literature, its etiopathogenesis has centered on the pluripotential capabilities of the epithelial lining of odontogenic cysts but our patient did not give a prior history of either cyst enucleation or tumor resection in the same region. It
seems that this tumor originated from retromolar mucous glands entrapped or embryonic remnants of the submandibular salivary gland within the mandibular bone which subsequently underwent neoplastic transformation.
Gemcitabine-(C4-amide)-[anti-HER2/neu] Anti-Neoplastic Cytotoxicty in Dual Combination with Mebendazole against Chemotherapeutic-Resistant Mammary Adenocarcinoma
Gemcitabine is a pyrimidine nucleoside analog that becomes triphosphorylated and competitively inhibits cytidine incorporation into DNA strands. Diphosphorylated gemcitabine irreversibly inhibits ribonucleotide reductase thereby preventing deoxyribonucleotide synthesis. Functioning as a potent chemotherapeutic, gemcitabine decreases neoplastic cell proliferation and induces apoptosis which accounts for its effectiveness in the clinical treatment of several leukemia and carcinoma cell types. A brief plasma half-life due to rapid deamination, chemotherapeutic-resistance and sequelae restrict gemcitabine utility in clinical oncology. Selective “targeted” gemcitabine delivery represents a molecular strategy for prolonging its plasma half-life and minimizing innocent tissue/organ exposure.